Propanc Biopharma reports preclinical PDAC data for PRP

Propanc Biopharma said its PRP candidate produced more than 90% mean tumor growth inhibition in pancreatic cancer models. The release also compared the preclinical data with Revolution Medicines' recently approved daraxonrasib.